Template:HSV-1 antiviral treatment: Difference between revisions

Line 1: Line 1:
===Anti-viral Treatment===
===Anti-viral Treatment===
''Treatment does not affect dormant virus in nerve ganglions → recurrent disease remains possible''
''Treatment does not affect dormant virus in nerve ganglions → recurrent disease remains possible''
*Antiviral drug options:
 
'''Normal Host'''
*Options:
**[[Acyclovir]] 40-80mg/kg PO divided in 3-4 doses for 5-7 days
**[[Acyclovir]] 40-80mg/kg PO divided in 3-4 doses for 5-7 days
***Can also be used as a cream or oral suspension (swish and swallow)<ref name="Mohan">Mohan RPS, Verma S, Singh U, Agarwal N. Acute primary herpetic gingivostomatitis. BMJ Case Reports. 2013;2013:bcr2013200074. doi:10.1136/bcr-2013-200074.</ref>
***Can also be used as a cream or oral suspension (swish and swallow)<ref name="Mohan">Mohan RPS, Verma S, Singh U, Agarwal N. Acute primary herpetic gingivostomatitis. BMJ Case Reports. 2013;2013:bcr2013200074. doi:10.1136/bcr-2013-200074.</ref>
**[[Valacyclovir]] (significantly higher bioavailability than acyclovir)
**[[Valacyclovir]] (significantly higher bioavailability than acyclovir)
**[[Famciclovir]]
**[[Famciclovir]]
'''Immunocompromised'''
*Options:
**[[Acyclovir]]
***5 mg/kg IV (over 1 hours) q8h x 7 days, OR
***400mg PO 5x/day x 14-21 days
**[[Famciclovir]] 500mg PO BID x 7 days, OR
**[[Valacyclovir]] 500mg PO BID x 5-10 days

Revision as of 20:56, 26 April 2016

Anti-viral Treatment

Treatment does not affect dormant virus in nerve ganglions → recurrent disease remains possible

Normal Host

  • Options:
    • Acyclovir 40-80mg/kg PO divided in 3-4 doses for 5-7 days
      • Can also be used as a cream or oral suspension (swish and swallow)[1]
    • Valacyclovir (significantly higher bioavailability than acyclovir)
    • Famciclovir

Immunocompromised

  • Options:
  1. Mohan RPS, Verma S, Singh U, Agarwal N. Acute primary herpetic gingivostomatitis. BMJ Case Reports. 2013;2013:bcr2013200074. doi:10.1136/bcr-2013-200074.